NLS Pharmaceutics (NLSP) Competitors $3.60 -0.03 (-0.83%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NLSP vs. NEOS, IMRX, MNPR, RPHM, MURA, DTIL, KRON, CDTX, VNRX, and THTXShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Neos Therapeutics (NEOS), Immuneering (IMRX), Monopar Therapeutics (MNPR), Reneo Pharmaceuticals (RPHM), Mural Oncology (MURA), Precision BioSciences (DTIL), Kronos Bio (KRON), Cidara Therapeutics (CDTX), VolitionRx (VNRX), and Theratechnologies (THTX). These companies are all part of the "medical" sector. NLS Pharmaceutics vs. Neos Therapeutics Immuneering Monopar Therapeutics Reneo Pharmaceuticals Mural Oncology Precision BioSciences Kronos Bio Cidara Therapeutics VolitionRx Theratechnologies Neos Therapeutics (NASDAQ:NEOS) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability. Is NEOS or NLSP more profitable? NLS Pharmaceutics has a net margin of 0.00% compared to Neos Therapeutics' net margin of -38.35%. Company Net Margins Return on Equity Return on Assets Neos Therapeutics-38.35% N/A -28.46% NLS Pharmaceutics N/A N/A N/A Do institutionals & insiders hold more shares of NEOS or NLSP? 33.1% of Neos Therapeutics shares are held by institutional investors. 3.8% of Neos Therapeutics shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer NEOS or NLSP? Neos Therapeutics received 492 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 63.94% of users gave Neos Therapeutics an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformNeos TherapeuticsOutperform Votes50063.94% Underperform Votes28236.06% NLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Which has stronger valuation & earnings, NEOS or NLSP? NLS Pharmaceutics has lower revenue, but higher earnings than Neos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeos Therapeutics$64.65M0.89-$16.90M-$0.34-3.38NLS PharmaceuticsN/AN/A-$12.17MN/AN/A Which has more volatility and risk, NEOS or NLSP? Neos Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.57, suggesting that its stock price is 157% less volatile than the S&P 500. Does the media refer more to NEOS or NLSP? In the previous week, NLS Pharmaceutics had 2 more articles in the media than Neos Therapeutics. MarketBeat recorded 3 mentions for NLS Pharmaceutics and 1 mentions for Neos Therapeutics. Neos Therapeutics' average media sentiment score of 0.00 equaled NLS Pharmaceutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend NEOS or NLSP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ANLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryNeos Therapeutics and NLS Pharmaceutics tied by winning 5 of the 10 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.75M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E RatioN/A9.36112.5515.07Price / SalesN/A386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book0.325.324.645.01Net Income-$12.17M$153.56M$119.13M$225.46M7 Day Performance-13.88%0.12%0.78%0.37%1 Month Performance-27.71%15.23%5.65%3.57%1 Year Performance445.29%41.16%36.90%29.42% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS Pharmaceutics0.2324 of 5 stars$3.60-0.8%N/A+408.8%$13.75MN/A0.006Gap UpNEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-2.61213Analyst ForecastNews CoverageHigh Trading VolumeIMRXImmuneering3.7702 of 5 stars$2.06-3.7%$12.60+511.7%-71.1%$61.09M$320,000.00-1.0860Short Interest ↓News CoveragePositive NewsMNPRMonopar Therapeutics3.9794 of 5 stars$17.31-2.9%$22.00+27.1%+432.0%$60.93MN/A-7.5310Gap UpRPHMReneo Pharmaceuticals2.3163 of 5 stars$1.82+5.2%$11.01+505.1%-76.8%$60.84MN/A-0.8430Gap DownMURAMural Oncology3.7954 of 5 stars$3.54-2.5%$16.00+352.0%N/A$60.32MN/A-0.34119DTILPrecision BioSciences4.0207 of 5 stars$8.31+0.4%$39.50+375.3%-24.6%$60.12M$87.64M39.97200Upcoming EarningsKRONKronos Bio3.5633 of 5 stars$0.98+0.1%$4.13+320.9%+17.4%$59.08M$6.29M-0.56100Short Interest ↓News CoverageCDTXCidara Therapeutics4.2839 of 5 stars$12.85+3.0%$29.67+130.9%-18.5%$58.62M$53.87M-0.5290Upcoming EarningsNews CoverageVNRXVolitionRx1.8302 of 5 stars$0.63flat$2.50+296.8%-18.3%$58.03M$770,000.00-1.5880News CoverageGap UpTHTXTheratechnologiesN/A$1.24-1.6%N/A+37.1%$57.02M$84.32M-12.40140 Related Companies and Tools Related Companies Neos Therapeutics Alternatives Immuneering Alternatives Monopar Therapeutics Alternatives Reneo Pharmaceuticals Alternatives Mural Oncology Alternatives Precision BioSciences Alternatives Kronos Bio Alternatives Cidara Therapeutics Alternatives VolitionRx Alternatives Theratechnologies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLSP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLSP Stock Alerts